



# Summary



Extending REDCap's Randomisation Capabilities to facilitate

**Bayesian Adaptive Randomisation** 

and dynamic randomisation via

**Biased Coin Minimisation** 

for the FORMAT Trial.



- Randomise to avoid bias.
- Aim to balance the number of participants allocated to each allocation group, e.g. intervention vs. control.
- Randomisation to allocation group is not random!
- Allocate sequentially from a list generated in advance.
- Blocks of varying size and permutation.

Block	Entry	Group
1	1	
1	2	C
1	3	C
1	4	
2	1	
2	2	C
3	1	C
3	2	
•••		



- Randomise to avoid bias.
- Aim to balance the number of participants allocated to each allocation group, e.g. intervention vs. control.
- Randomisation to allocation group is not random!
- Allocate sequentially from a list generated in advance.
- Blocks of varying size and permutation.

Block	Entry	Group	Used
1	1	- 1	<b>İ</b>
1	2	C	
1	3	C	
1	4	I	
2	1	ı	
2	2	C	
3	1	C	
3	2	ı	
•••			



- Randomise to avoid bias.
- Aim to balance the number of participants allocated to each allocation group, e.g. intervention vs. control.
- Randomisation to allocation group is not random!
- Allocate sequentially from a list generated in advance.
- Blocks of varying size and permutation.

Block	Entry	Group	Used
1	1	1	<b>İ</b>
1	2	C	<b>"</b>
1	3	C	
1	4	1	
2	1	1	
2	2	C	
3	1	C	
3	2	I	
•••			



- Randomise to avoid bias.
- Aim to balance the number of participants allocated to each allocation group, e.g. intervention vs. control.
- Randomisation to allocation group is not random!
- Allocate sequentially from a list generated in advance.
- Blocks of varying size and permutation.

Block	Entry	Group	Used
1	1	- 1	<b>"</b>
1	2	C	<b>"</b>
1	3	C	<b>†</b>
1	4	I	
2	1	I	
2	2	C	
3	1	C	
3	2	I	
•••			



- Randomise to avoid bias.
- Aim to balance the number of participants allocated to each allocation group, e.g. intervention vs. control.
- Randomisation to allocation group is not random!
- Allocate sequentially from a list generated in advance.
- Blocks of varying size and permutation.
- Strata to balance within subpopulations.

Stratu	ım: M			Stratu	m: F		
Block	Entry	Group	Used	Block	Entry	Group	Used
1	1	- 1	Ť	1	1	C	#
1	2	C	Ť	1	2	1	Ť
1	3	C	Ť	2	1	I	
1	4	I		2	2	C	
2	1	I		2	3	I	
2	2	C		2	4	C	
3	1	C		3	1	C	
3	2	I		3	2	I	
•••				•••			

#### The Stratified List: Limitations



Traditional Randomised Controlled Trial design has a long and successful

history, but:



- Trial design and statistical analysis laid down in advance.
- Trade off predictability (small blocks) with imbalance from incompletely allocated (larger) blocks.
- Cannot weight stratification factors.
- No capacity to vary allocations or allocation ratios while trial in progress.
- "One population, one drug, one disease"
  - → high costs, slow progress, high failure rate.


# Beyond the Stratified List: Adaptive Designs



#### FDA: Adaptive design

"allows for prospectively planned modifications ... based on accumulating data from subjects"

- Many different types, but potential modifications must be pre-specified.
- Example: response-adaptive randomisation:
  - More participants get promising treatments, ineffective treatments discarded.
- Can be more efficient when there is uncertainty around treatment effects (e.g. effectiveness, toxicity).



# Beyond the Stratified List: Adaptive Designs



- "Basket"
  - > evaluating multiple treatments for a single condition.



- "Umbrella"
  - > evaluating one treatment (drug) for multiple conditions



- "Platform":
  - Basket + Umbrella: multiple treatments, multiple conditions/populations.







"Treatment regimens for Mycobacterium abcessus (MABS) are highly variable, not evidence-based and involve complex, expensive and often poorly tolerated drug combinations for prolonged periods."

#### Aims:

- To build an iterative, standing, platform trial with innovative and adaptive properties to evaluate combinations of therapies for patients with MABS-PD (MABS pulmonary disease).
- Test therapies that are currently used and recommended in published international consensus guidelines and are the basis for the current treatment guidelines for MABS-PD.
- Once the best combinations have been established the platform described in the Master Protocol
  will have the capacity to add new treatments and to eliminate therapies because of futility as
  they either lack efficacy or cause unacceptable toxicity.
- The data obtained as part of the trial will be used to plan for new waves of the platform trial using novel therapeutic approaches that may be tested against the previously determined optimal approaches, thus leading in an iterative fashion to improving microbiological clearance and health outcomes associated with MABS-PD.





Why a platform - adaptive - approach for the FORMAT trial?

- MABS patient populations are very heterogeneous.
- Wide variety of treatment options in common usage.
- No strong evidence around relative effectiveness of common treatment regimens.
- Not possible to conceive a practical traditional trial design with reliable assumptions.
- Only the adaptive approach can facilitate

"Finding the Optimal Regimen"...






#### How to implement a platform approach for the FORMAT trial?

- Bayesian Adaptive Randomisation (BAR):
  - Define interim rules for dropping or adding treatment arms.
- Biased Coin Minimisation (BCM):
  - Stratified list is not an option because
    - > treatments arms will change
    - > stratification factors weighted differently
  - Adaptive randomisation algorithm required.

# Bayesian Adaptive Randomisation (BAR)



- Iterative process.
- Interim analysis results utilised to define parameters for next iteration.



Pre-specified changes only.

# Adaptive Randomisation: Biased Coin Minimisation



#### Three step process:

1. Compute an imbalance score for each treatment based on previous allocations and target allocation ratio.



2. Select the treatment with the smallest imbalance score as "preferred".



3. Calculate allocation probabilities according to preferred treatment and ratio.



# REDCap External Module

- Three randomisation events.
  - Different stratification factors.
  - Different factor weightings.
- Bayesian Adaptive Randomisation
  - Dynamically configurable midtrial.
- Biased Coin Minimisation
  - Necessary to support adaptivity.
  - Scope for weighting factors differently.

#### **☆** Randomization

Setup Dashboard Simulate

Set JSON configuration in External Module project settings. Configuration is currently set to:

```
"allocation field": "r1 grp",
    "allocation_event": "day_0_arm_1",
    "randomiser": {
        "class": "BiasedCoinMinimisation",
        "config": {
            "factors_weights": [
                { "factor_name": "r1_resist", "weighting": 0.5 },
                { "factor name": "r1 agecat", "weighting": 0.2 },
                { "factor name": "r1 sex", "weighting": 0.1 },
                 "factor name": "r1 loc", "weighting": 0.1 },
                { "factor name": "r1 cf", "weighting": 0.1 }
            "allocations ratios": [
                { "group": "1", "ratio": 1 },
                { "group": "2", "ratio": 1 },
                { "group": "3", "ratio": 1 }
            "base assignment probability": 70
},
    "allocation_field": "r2_mabsposgrp",
    "allocation_event": "week_6_arm_1",
```

# REDCap External Module

**Form Status** 



#### Randomisation1 Randomisation1 Data Access Group: 1101 AUS Site 01 ? Data Access Group: 1101 AUS Site 01 ? Editing existing Record ID 10151-1 Editing existing Record ID 10151-1 Event Name: Day 0 Event Name: Day 0 10151-1 10151-1 Record ID Record ID Age at randomisation (years) Age at randomisation (years) View equation View equation Macrolide resistance Macrolide resistance Yes Yes ~ \* must provide value \* must provide value Age category Age category Less than 12 years Less than 12 years \* must provide value \* must provide value Sex Sex Female V Female ~ \* must provide value \* must provide value Location Location AUS/NZL AUS/NZL \* must provide value \* must provide value **Cystic fibrosis Cystic fibrosis** Yes Yes ~ \* must provide value \* must provide value **Randomisation 1 Stratification Randomisation 1 Stratification** Randomisation 1 date/time Randomisation 1 date/time 18-09-2019 06:28:05 Now D-M-Y H:M:S 18-09-2019 06:28:05 Now D-M-Y H:M:S \* must provide value \* must provide value **Randomisation 1 Group Allocation Randomisation 1 Group Allocation** Randomised allocation 1 Randomised allocation 1 Intensive A **Randomise**

**Form Status** 

# REDCap External Module

- Comprehensive logging of allocation steps and calculations.
- API method for validation simulations.

```
andDBtest.R* ×

⇒ I Source on Save Q F → III

                                                                               --→ Run 🌖 →
  37 #no: of simulations and randomizations
      nsims=500 #no: of simulations/runs
  39 nrand=100 #no: of randomizations within a simulation
     t1<-proc.time()[[3]]
  41
      simRecords=list()
  43
      #for each simulation run
  45 - for (i in 1:nsims){
  46
        #1.clear the database: reset the target project (i.e. delete all records and reset
  47
        y<-postForm(uri=api_url_reset,
  48
  49
                      token = secret_token,
                      curl = curl_handle)
  50
  51
  52
        set.seed(20190625+i)
        site=paste0("s",sample(1:10,nrand,replace = T))
  54
  55
        sex=as.character(sample(1:2,nrand,replace = T))
  56
        #NOTE: sex and site should be replaced by the actual minimisation factors
  57
  58
        result=list()
```

		(Day 0)	
18/09/2019 06:33	luke.stevens		-Imbalance score for Factor r1_agecat=1 (weighting 0.2), Group=2 sat2of(2x0.1), № 1, weighted = 1 x 0.2 = 0.2
18/09/2019 06:33	luke.stevens	extended_randomis	-Factor r1_agecat=1 Group counts: 1 current=0, adjusted=(0+0) saleOn2\u00e40\u00e42\u00fc\u00e40\u00e42\u00e40\u00
18/09/2019 06:33	luke.stevens		-Imbalance score for Factor r1_resist=1 (weighting 0.5), Group=2 = san(প্রমুখ্য), e.2, weighted = 1 x 0.5 = 0.5
18/09/2019 06:33	luke.stevens	extended_randomis	-Factor r1_resist=1 Group counts: 1 current=0, adjusted=(0+0) នៅមហិវិទ្ធិសាលិខិnt=0, adjusted=(0+1)/1=1: 3 current=0, adjusted=(0+0) /1=0;
18/09/2019 06:33	luke.stevens		Total marginal imbalance score for Group=1 = ទាយ១២,29៨នេះ+0.1+0.1 = 1
18/09/2019 06:33	luke.stevens		-Imbalance score for Factor r1_cf=1 (weighting 0.1), Group=1 = 2/ (৪৯৫৫) ১৭০০) এeighted = 1 x 0.1 = 0.1
18/09/2019 06:33	luke.stevens		-Factor r1_cf=1 Group counts: 1 current=0, adjusted=(0+1)/1=1; 2 sotiore_nt参加.âdjusted=(0+0)/1=0; 3 current=0, adjusted=(0+0)/1=0;
18/09/2019 06:33	luke.stevens		-Imbalance score for Factor r1_loc=1 (weighting 0.1), Group=1 = 2/ (ইটিচেণ])+010.@eighted = 1 x 0.1 = 0.1
18/09/2019 06:33	luke.stevens		-Factor r1_loc=1 Group counts: 1 current=0, adjusted=(0+1)/1=1; 2 setione_nt=0,.adjusted=(0+0)/1=0; 3 current=0, adjusted=(0+0)/1=0;
18/09/2019 06:33	luke.stevens		-Imbalance score for Factor r1_sex=2 (weighting 0.1), Group=1 = 2 set2on1ye.0,2weighted = 1 x 0.1 = 0.1
18/09/2019 06:33	luke.stevens		-Factor r1_sex=2 Group counts: 1 current=0, adjusted=(0+1)/1=1; 2 setiore_nt争億.adjusted=(0+0)/1=0; 3 current=0, adjusted=(0+0)/1=0;
18/09/2019 06:33	luke.stevens		-Imbalance score for Factor r1_agecat=1 (weighting 0.2), Group=1 sat2oft2x0.t0, ≥ 1, weighted = 1 x 0.2 = 0.2
18/09/2019 06:33	luke.stevens	extended_randomis	-Factor r1_agecat=1 Group counts: 1 current=0, adjusted=(0+1) รอีฟอก⊋ัสมิติศิลิเลย ภาคอ:
18/09/2019 06:33	luke.stevens		-imbalance score for Factor r1_resist=1 (weighting 0.5), Group=1 = sati(মেথ্ৰ/Q, e.2, weighted = 1 x 0.5 = 0.5
18/09/2019 06:33	luke.stevens	extended_randomis	-Factor r1_resist=1 Group counts: 1 current=0, adjusted=(0+1) วิสิษัตก <u>2</u> หันพิทัยิทt=0, adjusted=(0+0)/1=0; 3 current=0, adjusted=(0+0) /1=0;
18/09/2019 06:33	luke.stevens	External Module extended_randomis Record 10151-1 (Day 0)	Stratification values are r1_resist=1 r1_agecat=1 r1_sex=2 r1_loc=1 sation_v0.0.2
18/09/2019 06:33	luke.stevens	External Module extended_randomis Record 10151-1 (Day 0)	***** Biased Coin Minimisation: Record 10151-1 ***** sation_v0.0.2

# Summing Up



- FORMAT First Patient First Visit scheduled for October 2019.
- Demand for adaptive designs is increasing.
- Developing expertise in adaptive trials is a strategic focus for us.
- Opportunities for REDCap in this space? Innovation!
  - Better support for common double-blind randomisation (allocate a randomisation number, not a group) / code break?
  - Extend core functionality (or hook points, API method) to support more types of randomisation e.g. BCM algorithms?
  - Multiple randomisations per project?
  - Supporting adaptive trials (i.e. mid-trial alterations)?

# Further Reading



- The Platform Trial: An Efficient Strategy for Evaluating Multiple Treatments Scott M Berry, Jason T Connor, Roger J Lewis JAMA; DOI 10.1001/jama.2015.2316
- Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls
   Peter Bauer, Frank Bretz, Vladimir Dragalin, FranZ Konig and Gernot Wassmer
   Statistics in Medicine; DOI 10.102/sim.6472
- Adaptive design clinical trials: review of the literature and ClinicalTrials.gov Laura E Bothwell, Jerry Avorn, Nazleen F Khan, Aaron S Kasselheim BMJ Open; DOI 10.1136/bmjopen-2017-018320
- Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry
   U.S. Department of Health and Human Services: Food and Drug Administration
- Randomization by minimization for unbalanced treatment allocation
   Baoguang Han, Nathan H Enas and Damien McEntagart
   Statistics in Medicine; DOI 10.1002/sim.3710



# Thank you.



# Step up to the microphone for any questions.

And thanks to the REDCap team at Vanderbilt University

Title: Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

Author: Paul A. Harris, Robert Taylor, Robert Thielke, Jonathon Payne, Nathaniel

Gonzalez, Jose G. Conde

Publication: Journal of Biomedical Informatics

Publisher: Elsevier

Date: April 2009

DOI: https://doi.org/10.1016/j.jbi.2008.08.010